CSL Behring acquires global commercialization rights to uniQure's hemophilia B gene therapy AMT-061

CSL Behring acquired exclusive global rights to commercialize AMT-061, a gene therapy for hemophilia B, from uniQure. uniQure will receive an upfront payment of $450 million and additional royalties.

“We are thrilled to enter into this commercialization and license agreement with CSL Behring, an ideal commercial partner with global reach and decades of expertise in hemophilia.”hemophilianewstoday.com

• 1 source
• hemophilianewstoday.comCSL Behring Gains Market Rights to Hemophilia B Gene Therapy AMT-061Joana Carvalho, PhDJun 25, 2020

Summarized from public sources; check the original articles before acting on it.